Dose adjusted EPOCH – Rituximab as first line treatment for high risk, aggressive B-NHL : a single center experience

In this report we presented 22 patients with high risk diffuse large B-cell lymphoma. Our results showed that DA-EPOCH-R is highly effective regimen in this group of patients. These results are conclusive with results of Garcia-Suarez and colleagues (Garcia-Suarez J et al. British journal of Haematology 2007 ; 136:276-285) who also find this regimen effective as first line treatment in DLBCL patients. Some of our patients were consolidated with autoHSCT due to high proliferation index or IPI≥3. Only 1 patient relapsed during follow up period. Of 6 patients who were transplated, all but one are still in CR. We conclude that DA-EPOCH-R is highly effective regimen as first line treatment in high risk diffuse large B-cell lymphoma.